Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells

Full text
Alves, Samara Rodrigues [1, 2] ; Colquhoun, Alison [3] ; Wu, Xiao Yu [2] ; Silva, Denise de Oliveira [1]
Total Authors: 4
[1] Univ Sao Paulo, Inst Chem, Dept Fundamental Chem, Lab Synthet & Struct Inorgan Chem Bioinorgan & Me, Av Prof Lineu Prestes, 748, B2T, BR-05508000 Sao Paulo, SP - Brazil
[2] Univ Toronto, Leslie Dan Fac Pharm, Adv Pharmaceut & Drug Delivery Lab, Toronto, ON M5S 3M2 - Canada
[3] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Av Prof Lineu Prestes 1524, BR-05508000 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Journal of Inorganic Biochemistry; v. 205, APR 2020.
Web of Science Citations: 0

Novel formulations of diruthenium(II,III)-NSAID (NSAID, non-steroidal anti-inflammatory drug) metallodrugs encapsulated into biocompatible terpolymer-lipid nanoparticles (TPLNs) to target glioblastoma cancer were developed. The nanoformulations of Ibuprofenate (RuIbp) and Naproxenate (RuNpx) metallodrugs were synthesized and characterized. The procedure rationally designed to avoid structural changes on the coordination sphere of the {[}Ru-2(NSAID)(4)](+) paddlewheel unit succeeded in giving colloidally stable and nearly spherical shaped loaded {[}Ru-2(NSAID)(4)]-TPLNs with appropriate parameters (similar to 90% loading efficiency; drug loading around 10%; particle size similar to 130 nm; zeta potential around - 40 mV). The maintenance of the {[}Ru-2(NSAID)(4)](+) framework was confirmed by spectroscopy and mass spectrometry. The encapsulation enhanced antiproliferative effects in U87MG cells for both metallodrugs. The RuIbp-TPLNs showed efficacy also against the cisplatin chemoresistant T98G cancer cells. Lack of significant effects for the loaded-Ibuprofen-TPLNs (HIbp-TPLNs) on both types of cells supports the key role of the dimetal core in the anticancer activity of the {[}Ru-2(NSAID)(4)](+) metallodrugs. The high cell viability ( > 70%) found for both types of cells suggests activity associated mainly to antiproliferative effects. The blank-TPLNs internalized into U87MG cell cytoplasm mostly at the first 6 h, by energy-dependent mechanism. The cell uptake of the Rulbp-TPLNs occurred during the first 24 h and it was enhanced in relation to the non-encapsulated metallodrug. The development of these novel metallodrug-loaded TPLN nanoformulations, which exhibit colloidal stability suitable for intravenous injection and enhanced drug cellular uptake, expands the perspective for diruthenium(II,III)-NSAID metallodrugs targeting brain glioblastoma cancer. (AU)

FAPESP's process: 14/23481-7 - Study of lipid-based nanoparticles as carriers for anticancer ruthenium metallodrugs
Grantee:Samara Rodrigues Alves
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 15/24252-4 - Study of lipid based nanoparticles as carriers for anticancer ruthenium metallodrugs
Grantee:Samara Rodrigues Alves
Support Opportunities: Scholarships abroad - Research Internship - Doctorate (Direct)
FAPESP's process: 14/23047-5 - Anticancer metallodrugs of ruthenium containing bioactive ligands: synthesis, interaction with biomolecules and preparation of biocompatible nanoparticle drug delivery systems
Grantee:Denise de Oliveira Silva
Support Opportunities: Regular Research Grants